Search
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalThe QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628]. … It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
Bemegride
go.drugbank.com/drugs/DB13740ExperimentalIt has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Roxatidine acetate
go.drugbank.com/drugs/DB08806InvestigationalIt is currently approved in South Africa under the tradename Roxit.
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Clesrovimab
go.drugbank.com/drugs/DB18877Approvedto provide passive immunization against RSV infection as an alternative means of protection. … [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]
Galidesivir
go.drugbank.com/drugs/DB11676Investigational[L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19. … Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus.
Danegaptide
go.drugbank.com/drugs/DB11821InvestigationalDanegaptide has been investigated for the treatment of Focus of Study is STEMI.
Trapidil
go.drugbank.com/drugs/DB09283ExperimentalTrapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney
Piclamilast
go.drugbank.com/drugs/DB01791ExperimentalIt has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. … The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast.